Drugs / AZD3366
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04588727 | Oct 2020 → Jan 2022 | cardiovascular disorder | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD3366 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04588727 ↗ |
| Known as | APT102 | “AZD3366 (APT102), a long-acting recombinant form of an optimized CD39L3 human apyrase, has effectively reduced ATP, ADP, and platelet aggregation and provided tissue protection...” PMID 38804212 ↗ May 2024 |
| Modality | Protein / enzyme biologic | “a long-acting recombinant form of an optimized CD39L3 human apyrase” PMID 38804212 ↗ May 2024 |
| Route | Intravenous | “following single intravenous (IV) ascending doses” NCT04588727 ↗ |